Effect of Jianpi Huatan Decoction on Advanced Colorectal Cancer

Colorectal Neoplasms Clinical Trial

Official title:

Efficacy Evaluation of Jianpi Huatan Decoction in the Treatment of Advanced Colorectal Cancer and Analysis of Dominant Population Characteristics and Methylation Characteristics

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05187481
• Other study ID #: CI2021A01803
• Status: Recruiting
• Phase: Phase 3
• Start date: November 15, 2021
• Est. completion date: July 2024

Study information

• Verified date: November 2021
• Source: Xiyuan Hospital of China Academy of Chinese Medical Sciences
• Contact: Yu Wu, Master
• Phone: 010-62835438
• Email: zoujianhua2021[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will take progression-free survival and overall survival as the main evaluation indexes, to evaluate the Efficacy of Jianpi Huatan Decoction in the Treatment of Advanced Colorectal Cancer. Decision Trees and Discriminant Analysis will be used to analyze the characteristics of dominant population combined with clinical data of patients. DNA methylation of the subjects will be detected to study the methylation characteristics of the preponderant population of Jianpi Huatan Decoction.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: July 2024
• Est. primary completion date: July 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients with colorectal cancer with clear pathological diagnosis and Western medicine diagnostic criteria.

2. TNM classification of stage IV disease according to National Comprehensive Cancer Network (NCCN) Guidelines.

3. Expected survival time is over 3 months.

4. The age of 18 years old or more.

5. According to the efficacy evaluation criteria for solid tumors (RECIST 1.1), there are measurable lesions.

6. Chemotherapy and/or targeted therapy are planned.

7. Signed informed consent.

Exclusion Criteria:

1. History of previous or combined malignancies except non-melanoma skin cancer, cervical cancer in situ, or bladder cancer (Tis and T1) received adequate treatment in the five years prior to screening.

2. Combined with severe heart, liver, lung and kidney disease.

3. Patients have intestinal obstruction can't take decoction and need intravenous high-energy nutrition. Patients have malabsorption syndrome or other disease affecting gastrointestinal absorption or have active peptic ulcer disease.

4. Any unstable condition or condition that may endanger patient safety and compliance with research, such as pregnancy, depression, manic-depressive disorder, obsessive-compulsive disorder, or schizophrenia.

5. The expected survival time is less than 3 months.

6. The researchers determine that they were not suitable for the study.

Related Conditions & MeSH terms

• Colorectal Neoplasms

Intervention

Drug:
• Jianpi Huatan dispensing granule
once a day in the morning and evening, 30 days as a course of treatment, a total of 3 courses.
• Placebo granule
once a day in the morning and evening, 30 days as a course of treatment, a total of 3 courses.

Locations

Country	Name	City	State
China	Xiyuan Hospital of China Academy of Chinese Medical Sciences	Beijing	Beijing

Sponsors (3)

Lead Sponsor	Collaborator
Xiyuan Hospital of China Academy of Chinese Medical Sciences	China Academy of Chinese Medical Sciences, Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival	From enrollment until disease progression or death	From date of randomization until the date of disease progression or date of death from any cause, whichever came first, assessed up to 100 months
Primary	Overall survival	From enrollment until death or end of the follow-up	From date of randomization until the date of death from any cause, assessed up to 100 months
Secondary	Survival rate	The 1-year, 2-year and 3-year survival rates of patients in the treatment group and the control group were analyzed	3 years
Secondary	Disease control rate	Efficacy was assessed according to RECIST 1.1 at the end of 3 months of treatment.	3 months
Secondary	Cancer fatigue score	Piper Fatigue Scale will be used.The fatigue of patients will be evaluated from 22 items of behavioral dimension, emotional dimension, sensory dimension and cognitive dimension. The higher the score of each dimension, the more serious the fatigue degree.	3 months
Secondary	Traditional Chinese Medicine(TCM )symptom grading table	Effective: after treatment, TCM symptom score decreased by more than 50% compared with that before treatment.; Effective: decrease < 50% and equal to 30%; Invalid: decrease < 30%. Note: the formula is: (before treatment - integral after treatment) / before treatment by 100%.	3 months
Secondary	The European Organization for Cancer Research and Treatment Core Quality of Life Questionnaire (EORTC QLQ-C30) score scale	The raw scores for the scales and single items were linearly transformed to values between 0 and 100 as described in the EORTC QLQ scoring manual. The mean and standard deviation of each scale/single item were calculated. A higher score for a functioning scale represented a healthier level of functioning, a higher score for the global health status scale represented a higher QOL, and a higher score for a symptom scale/item represented a worse level of symptomatology.	3 months
Secondary	the United States Eastern Oncology Collaboration Group (ECOG) score scale	ECOG scoring standard is an indicator of patients' general health status and tolerance to treatment based on their physical strength. ECOG physical condition rating standard score 0-5 points. A minimum score of 0 indicates normal activity, a higher score indicates less physical activity, and a score of 5 indicates death.	3 months